Changes in Beneficial Ownership · 4
Biohaven Ltd.
BHVNNYSEEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1789683308.xml
Filing details
- Report period
- 2026-09-15
- Issuer
- Biohaven Ltd.
- Issuer CIK
- 0001935979
- Trading symbol
- BHVN
Reporting owner 1
- Name
- Gentile Kimberly
- Reporting owner CIK
- 0001704186
- Relationship
- Officer
- Officer title
- SVP, Clinical Operations
- Address
- C/O BIOHAVEN LTD., 215 CHURCH STREET, NEW HAVEN, CT, 06510
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to buy) | 12.34 | 2026-09-15 | A · Form 4 | 1,000 | A | 0 | [F1] | 2036-09-15 | Common Shares | 1,000 | 1,000[F2] | I | By Son |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- I
- Indirect
Footnotes
- F1
- The shares underlying this option vest in four equal installments on September 15, 2026, 2027, 2028 and 2029, subject to the Reporting Person's son's continuous service with the Issuer at each vesting date.↩ 1
- F2
- Represents a stock option granted to the Reporting Person's son in connection with the commencement of his employment with the Issuer. The Reporting Person disclaims beneficial ownership of all securities held by her son, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.↩ 1
Signature 1
- Signed
- /s/ George Clark, Attorney-in-Fact
- Date
- 2026-09-17
Company context
Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, obesity, neuroscience, and oncology. The Company is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms. Biohaven's extensive clinical and preclinical programs include Kv7 ion channel modulation for epilepsy; MoDE and TRAP extracellular protein degradation for immunological diseases; and myostatin inhibition for neuromuscular and metabolic diseases, including obesity.